Participant flow

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Investigators choice of Letrozole 2.5 mg po qd continuously, tamoxifen 20mg po bid continuously, paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d, 3 wks on, 1 wk off, Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d, Topotecan 4.0mg/m2 over 30 min on day 1,8 and 15 of a 28 day cycle. For each arm, 1 cycle - 28 days

   id

   FG000

   title

   Arm A - Control Arm

2. description

   Trametinib 2 mg po daily continuous treatment, For each arm, 1 cycle = 28 days

   id

   FG001

   title

   Arm B - Experimental Arm

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         130

      2. group Id

         FG001

         num Subjects

         130

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         88

      2. group Id

         FG001

         num Subjects

         0

      type

      Crossover from Arm A to Arm B

   3. achievements

      1. group Id

         FG000

         num Subjects

         120

      2. group Id

         FG001

         num Subjects

         116

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         14

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

A total of 260 patients enrolled before accrual closed on 04/10/2018.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice